Nerlynx (neratinib tablets - Puma) — Cigna
Breast Cancer – Adjuvant Therapy
Initial criteria
- Patient age ≥ 18 years AND
- Patient will not be using this medication in combination with HER2 antagonists (e.g., trastuzumab, pertuzumab) AND
- Patient has HER2-positive breast cancer AND
- EITHER the medication is requested for extended adjuvant therapy after the patient has completed 1 year of adjuvant therapy with an intravenous trastuzumab product OR the patient has tried adjuvant therapy with an intravenous trastuzumab product and could not tolerate 1 year of therapy
Approval duration
1 year